Evidence map›Paper›PMID 31004320›Full record

ArticleMolecular neurobiology2019

Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice.

Marta Kruk-Slomka, Izabela Banaszkiewicz, Tomasz Slomka, Grazyna Biala

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. A novel allosteric modulator of the cannabinoid CBNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marta Kruk-SlomkaDepartment of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4a Street, 20-093, Lublin, Poland. marta.kruk@umlub.pl.ORCID http://orcid.org/0000-0001-9201-7181
Izabela BanaszkiewiczDepartment of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4a Street, 20-093, Lublin, Poland.
Tomasz SlomkaDepartment of Mathematics and Medical Biostatistics, Medical University of Lublin, Jaczewskiego 4 Street, 20-954, Lublin, Poland.
Grazyna BialaDepartment of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4a Street, 20-093, Lublin, Poland.
Medical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The connection between the endocannabinoid system (ECS) and schizophrenia is supported by a large body of research. The ECS is composed of two types cannabinoid (CB: CB1 and CB2) receptors and their endogenous ligands, endocannabinoids. The best-known endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are intracellularly degraded by fatty acid hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. Thus, the function of ECS might be modulated in a direct way, through CB receptor ligands or indirectly by FAAH and MAGL inhibitors. We evaluated that the direct influence of ECS, using FAAH (URB 597) and MAGL (JZL 184) inhibitors, on the schizophrenia-like effects in mice. The behavioral schizophrenia-like symptoms were obtained in animals by using N-methyl D-aspartate (NMDA) receptor antagonists, MK-801. An acute administration of MK-801 (0.3 and 0.6 mg/kg) induced psychotic symptoms in rodents, manifested as the increase in locomotor activity, measured in actimeters, as well as the memory impairment, assessed in the passive avoidance (PA) task. We revealed that an acute administration of URB 597, at the dose of 0.3 mg/kg, attenuated MK-801 (0.6 mg/kg)-induced memory impairment. In turn, an acute administration of URB 597 at a higher dose (1 mg/kg) potentiated MK-801 (0.3 mg/kg)-induced memory impairment. Similarly, an acute administration of JZL 184 (20 and 40 mg/kg) intensified an amnestic effect of MK-801 (0.3 mg/kg). Moreover, an acute injection of JZL 184 (1 mg/kg) potentiated hyperlocomotion is provoked by MK-801 (0.3 and 0.6 mg/kg) administration. The present findings clearly indicate that ECS, through an indirect manner, modulates a variety of schizophrenia-like responses in mice.

Indexed as

CognitionAmidohydrolasesAnimalsAvoidance LearningBenzamidesBenzodioxolesCarbamatesDizocilpine MaleateEnzyme InhibitorsFatty Acid Amide HydrolasesInjectionsMaleMemoryMiceMotor ActivityPiperidinesAmidohydrolasesBenzamidesBenzodioxolesCarbamatescyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterDizocilpine MaleateEnzyme InhibitorsFatty Acid Amide HydrolasesJZL 184PiperidinesEndocannabinoidsFAAHMAGLMiceMK-801Schizophrenia-like symptoms

Identifiers

PMID31004320
PMCPMC6815283
OpenAlexW2938073730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.